Abstract Details

Title Prognostic Factors in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Single Center Experience

Topic Autoimmune Neurology

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-030

Objective We evaluated patients with MOG antibody disease (MOGAD) in terms of clinical and radiological features and tried to assess prognostic factors.

Background MOGAD is a neuro-inflammatory disease which is recognized as a separate demyelinating disease with specific clinical and paraclinical features. The differential diagnosis of MOGAD is notoriously difficult.

Design/Methods We retrospectively analyzed the clinical and radiological data of patients who were followed in the Department of Neurology, Istanbul University Faculty of Medicine. In our study, patients with a definite diagnosis of MOGAD were included. Patients were interviewed in the clinic or by phone, if necessary. Statistical evaluations were performed using independent-samples Mann Whitney U, Fisher exact, and log-rank tests.

Results

MOG antibodies were requested for 495 patients, and 23 tests were positive. Twenty patients (male: 10, female: 10, median age at onset: 33 years (95% CI: 25-42) with a mean follow-up of 51 months (95% CI: 15-120) with a definite diagnosis of MOGAD were included in the study. The median time to second relapse in males was 7 months (95% CI: 2-11), and in females it was 32 months (95% CI: 14-49)(p=0.054).Cerebrospinal fluid analysis (CSF) was performed in 15 patients. Seven (46.6%) of them had pathological values. The time to the second attack in patients with an elevated CSF protein level tended to be shorter than in patients with a normal CSF protein level (91 vs. 12 months; p=0.063). Seventeen (85.0%) patients received high dose steroid treatment; 13 of them recovered completely, Most of the patients received azathioprine (16), others rituximab (3), IVIG (2), mycophenolate mofetil (4), and cyclophosphamide (2).

Conclusions Patients with MOGAD generally have a favorable prognosis. We observed frequent CSF OCBs in female patients. Additionally, the disease tends to have a worse prognosis in males. The disease tends to progress worse in patients with an elevated CSF protein.

Authors/Disclosures
Murat Kurtuncu, MD (Istanbul University) PRESENTER	Dr. Kurtuncu has nothing to disclose.
Volkan M. Abayli, Jr.	Mr. ABAYLI has nothing to disclose.
Tuncay Gunduz, MD (ISTANBUL UNIVERSITESI NOROLOJI SERVISI)	The institution of Dr. Gunduz has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Pharmaceuticals. Dr. Gunduz has received research support from Turkish Neuroimmunology Society.
Mefkure Eraksoy, MD (ISTANBUL UNIVERSITY)	Dr. Eraksoy has nothing to disclose.

��ɫ��

��ɫ��